Skip to main content
. Author manuscript; available in PMC: 2022 Nov 22.
Published in final edited form as: J Alzheimers Dis. 2019;72(4):1077–1087. doi: 10.3233/JAD-190643

FIGURE 1. AMB prevalence increases across neuropathological substrates.

FIGURE 1

Each column represents % of cases with present AMB in each pathological substrate group. Logistic regression was used to assess AMB prevalence differences between groups. Number of cases within group reflected in each bar. ** refers to p=0.001, * refers to p < 0.050 significance. AMB prevalence increases across a) CERAD scores and b) Braak & Braak stages (except Braak 0).